FGI Surges 190% After 500% EPS Revision; Biotech, Tech Run Hot
FGI Industries exploded 190% to $11.17 after an analyst revision targeting 500% next-year EPS growth, signaling a fundamental re-rating of this consumer cyclical play. Skillz added 52% on a modest 1pp EPS revision, indicating elevated price sensitivity to earnings upgrades in mobile gaming. Healthcare and tech names LEGN, CRDO, and TGEN each gained 28-39% on smaller EPS adjustments, pointing to broad momentum across sectors despite thin news catalysts.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| FGI | Consumer Cyclical | 2026-04-13 | N/A | +190.1% |
| SKLZ | Communication Services | 2026-04-12 | +1.0pp | +52.0% |
| LEGN | Healthcare | 2026-04-14 | +0.4pp | +39.3% |
| CRDO | Technology | 2026-04-13 | +0.8pp | +31.4% |
| TGEN | Industrials | 2026-04-13 | +4.0pp | +28.4% |
FGI — FGI Industries Ltd
FGI Industries climbed from $3.85 to $11.17 in eight calendar days after the screener flagged a 500% next-year EPS growth projection, an extreme figure that signaled the analyst community had dramatically mispriced the company's earnings power. Consumer cyclical stocks rarely absorb 500% growth revisions without a corresponding fundamental catalyst — in this case the market appears to be pricing in either a major contract win, a restructuring of operations, or a sector-wide demand recovery. The 190% price appreciation preceded any confirmed news, suggesting early movers recognized the disparity between consensus estimates and realistic forward earnings.
View screener snapshot from 2026-04-13 →SKLZ — Skillz Inc
Skillz gained 52% on an EPS revision of just 1.0 percentage point, moving from 34.9% to 35.8% projected growth — a disproportionate response that reveals high elasticity to earnings revisions in this name. Mobile gaming platforms operating in Communication Services tend to have high short interest and low analyst coverage, meaning even small upward revisions can trigger short covering and momentum-driven buying. The stock rose from $2.46 to $3.74, suggesting the prior price had over-discounted downside risk and that the market was primed for any positive earnings signal.
View screener snapshot from 2026-04-12 →LEGN — Legend Biotech Corp ADR
Legend Biotech added 39.3% from $18.69 to $26.03 following a negligible 0.4pp EPS revision to 312.3% projected growth, indicating the price move was driven by sector momentum and clinical catalyst anticipation rather than earnings estimate mechanics. The company's CAR-T therapy pipeline for multiple myeloma has been an ongoing focus for healthcare funds; the screener caught a micro-increase in growth projections that coincided with a broader re-rating of early-commercialization biotech names. Without news, the gain reflects sector rotation into healthcare risk-on positions.
View screener snapshot from 2026-04-14 →CRDO — Credo Technology Group Holding Ltd
Credo Technology Group gained 31.4% to $176.54 from a detection price of $134.36, powered by a 0.8pp upward revision in next-year EPS growth from 42.5% to 43.2%. Credo's high-speed interconnect solutions sit squarely in the AI infrastructure supply chain, and the tech sector has been running on AI capex optimism throughout 2026. The EPS revision reinforced existing bullish theses about data center demand, with the modest estimate change serving as validation that growth projections remain intact rather than being revised down — a critical signal for semiconductor-adjacent names where investors are acutely sensitive to any sign of demand moderation.
View screener snapshot from 2026-04-13 →TGEN — Tecogen Inc
Tecogen rose 28.4% from $3.63 to $4.66 after the screener detected the largest absolute EPS revision among the group — a 4.0pp jump to 163.3% next-year growth. The move reflects clean energy and industrial sector momentum, where investors are rewarding companies with improving earnings power tied to distributed power generation and cogeneration demand. The magnitude of the revision suggested either improving contract flow or margin expansion that the prior consensus had not adequately priced, and the market responded by bringing the stock price closer to a valuation consistent with the updated earnings trajectory.
View screener snapshot from 2026-04-13 →Today's performance confirms that even minor EPS revisions can trigger outsized price moves when stocks are mispriced relative to realistic earnings power, and that AI-linked tech, early-commercialization biotech, and clean energy industrials are capturing the majority of risk-on capital rotation in this market environment.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →